 Aminoisobutyric Acids
"Aminoisobutyric Acids" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of compounds that are derivatives of the amino acid 2-amino-2-methylpropanoic acid.
| Descriptor ID |
D000621
|
| MeSH Number(s) |
D02.241.081.114.968.249 D12.125.070.075 D12.125.190.055
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Aminoisobutyric Acids".
Below are MeSH descriptors whose meaning is more specific than "Aminoisobutyric Acids".
This graph shows the total number of publications written about "Aminoisobutyric Acids" by people in this website by year, and whether "Aminoisobutyric Acids" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 0 | 1 | 1 | | 2017 | 0 | 1 | 1 | | 2018 | 0 | 3 | 3 | | 2019 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Aminoisobutyric Acids" by people in Profiles.
-
Kiser JJ. Safety of Hepatitis C Viral Protease Inhibitors in Compensated Cirrhotics: Lingering Concerns Put to Rest? Clin Infect Dis. 2019 10 30; 69(10):1665-1666.
-
Wyles D, Weiland O, Yao B, Weilert F, Dufour JF, Gordon SC, Stoehr A, Brown A, Mauss S, Zhang Z, Pilot-Matias T, Rodrigues L, Mensa FJ, Poordad F. Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection. J Hepatol. 2019 05; 70(5):1019-1023.
-
Flamm S, Mutimer D, Asatryan A, Wang S, Rockstroh J, Horsmans Y, Kwo PY, Weiland O, Villa E, Heo J, Gane E, Ryder SD, Welzel TM, Ruane PJ, Agarwal K, Ng TI, Xue Z, Lovell SS, Krishnan P, Kopecky-Bromberg S, Trinh R, Mensa FJ, Wyles DL. Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis. J Viral Hepat. 2019 03; 26(3):337-349.
-
Perng W, Tang L, Song PXK, Tellez-Rojo MM, Cantoral A, Peterson KE. Metabolomic profiles and development of metabolic risk during the pubertal transition: a prospective study in the ELEMENT Project. Pediatr Res. 2019 02; 85(3):262-268.
-
Wyles D, Poordad F, Wang S, Alric L, Felizarta F, Kwo PY, Maliakkal B, Agarwal K, Hassanein T, Weilert F, Lee SS, Kort J, Lovell SS, Liu R, Lin CW, Pilot-Matias T, Krishnan P, Mensa FJ. Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial. Hepatology. 2018 02; 67(2):514-523.
-
Piccolo BD, Mercer KE, Bhattacharyya S, Bowlin AK, Saraf MK, Pack L, Chintapalli SV, Shankar K, Adams SH, Badger TM, Yeruva L. Early Postnatal Diets Affect the Bioregional Small Intestine Microbiome and Ileal Metabolome in Neonatal Pigs. J Nutr. 2017 08; 147(8):1499-1509.
-
Kwo PY, Poordad F, Asatryan A, Wang S, Wyles DL, Hassanein T, Felizarta F, Sulkowski MS, Gane E, Maliakkal B, Overcash JS, Gordon SC, Muir AJ, Aguilar H, Agarwal K, Dore GJ, Lin CW, Liu R, Lovell SS, Ng TI, Kort J, Mensa FJ. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol. 2017 08; 67(2):263-271.
-
Gane E, Poordad F, Wang S, Asatryan A, Kwo PY, Lalezari J, Wyles DL, Hassanein T, Aguilar H, Maliakkal B, Liu R, Lin CW, Ng TI, Kort J, Mensa FJ. High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis. Gastroenterology. 2016 10; 151(4):651-659.e1.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|